ZEVRA THERAPEUTICS, INC. (ZVRA) Form 8-K — Nov 3, 2026
Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, up 45% from $26.1 million in Q3 2025, driven by $34.0 million from MIPLYFFA for Niemann-Pick disease type C. The company swung to net income of $19.2 million ($0.31 basic EPS) from a $(0.5) million loss a year ago. Balance sheet strength is a highlight: cash, cash equivalents and investments totaled $270.9 million at September 30, 2026, with long-term debt eliminated from the prior year's $61.9 million. Shares outstanding were 59.4 million (68.97 million fully diluted).
Key figures
- Eps
- 0.31
- Revenue
- 37800000
- Net Income
- 19200000
- Total Debt
- 0
- Revenue Yoy
- 45% increase vs Q3 2025 ($26.1M)
- Total Assets
- 313575000
- Cash Position
- 270900000
- Shares Outstanding
- 59439959
- Diluted eps
- 0.26
- Rnd expense q3 2026
- 4900000
- Sga expense q3 2026
- 19100000
- Fully diluted shares
- 68968909
- Miplyffa net revenue
- 34000000
- Eap patients enrolled
- 134
- Eap net reimbursements
- 3600000
- Operating expenses q3 2026
- 24100000
- Discover trial patients enrolled
- 72
- Miplyffa prescription enrollments total
- 197
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.